摘要
目的比较不同剂量米非司酮治疗子宫肌瘤的疗效及安全性。方法 102例子宫肌瘤患者,采用抽签法分为高剂量组和低剂量组,每组51例。两组患者均接受米非司酮治疗,高剂量组给予米非司酮剂量为25.0 mg/d,低剂量组给予米非司酮剂量为12.5 mg/d,均于月经来潮第1天开始治疗,睡前口服。比较两组临床疗效;治疗前后血清卵泡刺激素(FSH)、雌激素(E2)、孕酮(P)水平变化情况;治疗前后子宫肌瘤大小变化情况;不良反应发生情况。结果低剂量组治疗总有效率为94.1%,高于高剂量组的78.4%,差异具有统计学意义(P<0.05)。治疗后,两组血清FSH、E2、P水平均低于治疗前,差异具有统计学意义(P<0.05);两组血清FSH、E2、P水平比较差异无统计学意义(P>0.05)。治疗后,两组子宫肌瘤大小均较治疗前明显缩小,差异具有统计学意义(P<0.05);两组子宫肌瘤大小比较差异无统计学意义(P>0.05)。高剂量组治疗期间出现恶心呕吐5例、皮疹3例,不良反应发生率为15.7%(8/51);低剂量组治疗期间出现恶心呕吐1例、皮疹2例,不良反应发生率为5.9%(3/51);低剂量组不良反应发生率显著低于高剂量组,差异具有统计学意义(P<0.05)。结论每天给予剂量为12.5 mg米非司酮治疗子宫肌瘤,能显著提高临床疗效,降低不良反应发生率,值得临床借鉴。
Objective To compare the efficacy and safety of different doses of mifepristone in the treatment of uterine fibroids. Methods A total of 102 uterine fibroids patients were divided by lottery method into high-dose group and low-dose group, with 51 cases in each group. High-dose group received 25.0 mg/d of mifepristone, and low-dose group received 12.5 mg/d of mifepristone. Comparison were made on clinical efficacy, changes of serum follicle stimulating hormone(FSH), estrogen(E2) and progesterone(P) levels before and after treatment, the changes of uterine fibroid size before and after treatment and the occurrence of adverse reactions between the two groups. Results Low-dose group had higher total treatment effective rate as 94.1% than 78.4% in high-dose group, and the difference was statistically significant(P<0.05). After treatment, both groups had lower serum FSH, E2 and P than those before treatment, and the difference was statistically significant(P<0.05). Both groups had no statistically significant difference in serum FSH, E2 and P(P>0.05). After treatment, both groups had significantly smaller size of uterine fibroids than those before treatment, and the difference was statistically significant(P<0.05). Both groups had no statistically significant difference in size of uterine fibroids(P>0.05). High-dose group had 5 cases of nausea and vomiting, 3 cases of rash, and the incidence of adverse reactions was 15.7%(8/51), and the low-dose group had 1 case of nausea and vomiting, 2 cases of rash, and the incidence of adverse reactions was 5.9%(3/51). Low-dose group had significantly lower incidence of adverse reactions than high-dose group, and the difference was statistically significant(P<0.05). Conclusion Daily dose of 12.5 mg of mifepristone in the treatment of uterine fibroids can significantly improve the clinical efficacy and reduce the incidence of adverse reactions, and it is worthy of clinical reference.
作者
高磊
周文婷
张春玲
GAO Lei;ZHOU Wen-ting;ZHANG Chun-ling(Department of Gynecology,Shandong Tai’an Central Hospital,Tai’an 271000,China)
出处
《中国实用医药》
2019年第4期9-10,共2页
China Practical Medicine
关键词
米非司酮
子宫肌瘤
高剂量
低剂量
治疗效果
Mifepristone
Uterine fibroids
High dose
Low dose
Treatment effect
